Literature DB >> 25740466

The TNM system (version 7) is the most accurate staging system for the prediction of loss of life expectancy in differentiated thyroid cancer.

Karina Tanase1, Elena-Daphne Thies1,2, Uwe Mäder3, Christoph Reiners1, Frederik A Verburg1,4.   

Abstract

OBJECTIVE: Many prognostic systems have been developed for differentiated thyroid cancer. It is unclear which one of these performs 'best'. Our aim was to compare staging systems applicable to our patient database to identify which best predicts DTC-related loss of life expectancy and DTC-specific mortality.
DESIGN: Database study of patients with DTC treated in our centre between 1978 (earliest available data) up to and including 1 July 2014. All were staged in accordance with the AMES, Clinical Class, Memorial Sloan Kettering, Ohio State University, TNM versions 5 and 6/7, University of Alabama, University of Münster and qTNM systems. PATIENTS: A total of 2257 patients with differentiated thyroid cancer. MEASUREMENTS: Loss of life expectancy expressed as relative survival and thyroid cancer-specific mortality. Comparison was based on P values of univariate Cox regression analyses as well as analysis of the proportion of variance explained (PVE).
RESULTS: Median available follow-up time was 7·2 years (range: 0-35·1 years). Three hundred and twenty-seven patients died, 149 of whom died of DTC. Version 7 of the TNM system was best for predicting DTC-related mortality (P = 7·1 × 10-52 ; PVE = 0·296), followed by TNM version 5 (P = 6·7 × 10-44 ; PVE = 0·255). For prediction of loss of life expectancy, version 7 of the TNM system was also best, closely followed by the Clinical Class system (P both < 2 × 10-16 ).
CONCLUSIONS: The UICC/AJCC TNM system version 7 outperforms other prognostic classification systems based on extent of disease at the start of treatment both for prediction of differentiated thyroid cancer-related death and for prediction of loss life expectancy.
© 2015 John Wiley & Sons Ltd.

Entities:  

Year:  2015        PMID: 25740466     DOI: 10.1111/cen.12765

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  Eighth edition of AJCC staging for differentiated thyroid cancer: Is stage I appropriate for T4/N1b patients aged 45-55 years?

Authors:  Pedro Weslley Rosario
Journal:  Endocrine       Date:  2017-03-30       Impact factor: 3.633

2.  Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality.

Authors:  Alexis Vrachimis; Burkhard Riemann; Uwe Mäder; Christoph Reiners; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-23       Impact factor: 9.236

Review 3.  Metastasis: an early event in cancer progression.

Authors:  Yijun Hu; Xiya Yu; Guixia Xu; Shanrong Liu
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-29       Impact factor: 4.553

4.  The Relationship of Clinicopathological Factors of the Tumor with Preoperative TSH Level in Papillary Thyroid Cancers.

Authors:  Evren Besler; Bulent Citgez; Nurcihan Aygun; Mustafa Fevzi Celayir; Müveddet Banu Yılmaz Ozguven; Mehmet Mihmanli; Sitki Gurkan Yetkin; Mehmet Uludag
Journal:  Eurasian J Med       Date:  2018-12-03

5.  Optimal Cut-Off Values of Lymph Node Ratio Predicting Recurrence in Papillary Thyroid Cancer.

Authors:  Seul Gi Lee; Joon Ho; Jung Bum Choi; Tae Hyung Kim; Min Jhi Kim; Eun Jeong Ban; Cho Rok Lee; Sang-Wook Kang; Jong Ju Jeong; Kee-Hyun Nam; Sang Geun Jung; Young Suk Jo; Jandee Lee; Woong Youn Chung
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

6.  Clinical preliminary study on the correlation between nodular goitre and papillary thyroid carcinoma.

Authors:  Junbiao Huang; Changwei Lin; Yifei Chen; Xiaorong Li
Journal:  Transl Cancer Res       Date:  2020-06       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.